Ifosfamide/Carboplatin/Etoposide/Rituxan Followed by Zevalin in Relapsed/Refractory Intermediate Grade B-Cell Lymphoma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2003-10-31

Study Completion Date

2005-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In this Multicenter trial, we will evaluate the feasibility, toxicity, and efficacy of treatment with 90Y Zevalin following a short course of salvage chemotherapy in patients with relapsed/refractory intermediate grade B-cell non-Hodgkin's lymphoma.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Dose Augmented Rituximab and ICE for Pts With Primary Refractory and Poor Risk Relapsed Aggressive B-Cell NHL

NCT00588094

Lymphoma B-cell Non-Hodgkin's Lymphoma

COMPLETED PHASE2

Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies

NCT04205409

Recurrent Chronic Lymphocytic Leukemia Recurrent Diffuse Large B-Cell Lymphoma Recurrent Follicular Lymphoma +15 more

ACTIVE_NOT_RECRUITING PHASE2

Carfilzomib Plus Belinostat in Relapsed/Refractory NHL

NCT02142530

Non-Hodgkin Lymphoma Diffuse Large B-cell Lymphoma Mantle Cell Lymphoma +2 more

COMPLETED PHASE1

A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL)

NCT05784441

Relapsed or Refractory B Cell Non-Hodgkin Lymphoma

ACTIVE_NOT_RECRUITING PHASE1

Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

NCT05633615

Diffuse Large B-Cell Lymphoma Grade 3b Follicular Lymphoma Primary Mediastinal (Thymic) Large B-Cell Lymphoma +4 more

RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Upon determination of eligibility, patients will receive:

* Ifosfamide + Carboplatin + Etoposide + Rituximab

Patients showing no response to this combination regimen will receive 90Y Zevalin after two cycles or when progression is clearly documented. In responding patients, four cycles will be administered, followed by 90Y Zevalin.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Non-Hodgkins Lymphoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ifosfamide

Intervention Type DRUG

Carboplatin

Intervention Type DRUG

Etoposide

Intervention Type DRUG

Rituximab

Intervention Type DRUG

90Y Zevalin

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

To be included in this study, you must meet the following criteria:

* Intermediate grade CD20-positive B-cell non-Hodgkin's lymphoma
* Persistent lymphoma after one or two previous chemotherapy regimens
* Patients should not be considered candidates for high-dose chemotherapy
* Ability to perform activities of daily living with assistance
* Measurable or evaluable disease
* Age \> 18 years
* Adequate bone marrow, liver and kidney function

Exclusion Criteria

You cannot participate in this study if any of the following apply to you:

* Patients with impaired bone marrow reserve
* Female patients who are pregnant or lactating
* Serious active infection at the time of treatment
* Any other serious underlying condition
* Brain or meningeal) with lymphoma
* HIV or AIDS-related lymphoma
* Received external beam radiation therapy to \> 25% of active bone marrow.
* History of other cancers, either active or treated

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No